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doi:10.1016/j.jfma.2011.11.028Background/Purpose: Clopidogrel is associated with a high incidence of upper gastrointestinal
bleeding in high-risk patients. However, the characteristic upper gastrointestinal lesions in
symptomatic clopidogrel users remain unclear. The aims of this study were to investigate
the characteristics of endoscopic findings in clopidogrel users undergoing endoscopy for upper
gastrointestinal symptoms and to compare the clinical characteristics and upper gastrointes-
tinal lesions between symptomatic clopidogrel and aspirin users.
Methods: This observational study included 215 consecutive patients receiving clopidogrel
(nZ 106) or low-dose aspirin (nZ 109) therapy who underwent endoscopy for dyspeptic symp-
toms. The upper gastrointestinal lesions were carefully assessed, and a complete medical
history was obtained by a standard questionnaire.
Results: The frequencies of hemorrhagic spots, erosions and peptic ulcers in the symptomatic clo-
pidogrel userswere 25%, 39% and 39%, respectively. Among the peptic ulcer patients on clopidogrel
therapy, the distributions of ulcers were 78%, 5% and 17% in the stomach, duodenum and both,
respectively. Compared with the aspirin group, the clopidogrel group was older and had higher
frequencies of past ulcer history and past gastrointestinal bleeding history in their clinical charac-
teristics. By contrast, the clopidogrel users had a lower prevalence of active Helicobacter pyloriGastroenterology, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813,
v.tw (F.-W. Tsay).
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706 T.-J. Tsai et al.infectionthanaspirinusers (17%vs.35%, respectively,pZ 0.007).Regarding to theendoscopicfind-
ings, the clopidogrel users had higher frequencies of hemorrhagic spots (25% vs. 10%) and peptic
ulcer (39% vs. 24%) than aspirin users (pZ 0.004 and 0.027, respectively).
Conclusion: Most peptic ulcers in clopidogrel users are located in the stomach. The frequencies of
hemorrhagic spots andpepticulcers in symptomatic clopidogrelusersarehigher than those in symp-
tomatic aspirin users.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.therapies and underwent diagnostic endoscopy for dyspepticIntroduction
Antiplatelet agents such as aspirin and clopidogrel are widely
used for primary and secondary prevention of cardiovascular
and cerebrovascular diseases.1 However, use of either
aspirin or clopidogrel is associated with adverse gastroin-
testinal effects. Aspirin irreversibly inhibits cyclo-oxygenase
(COX) activity in both platelet and gastrointestinal mucosa.
Thus, the synthesis of cytoprotective prostaglandin in the
gastrointestinal tract is reduced, and gastroduodenal lesions
can subsequently develop.2 Endoscopic study of asymptom-
atic mini-dose aspirin (100 mg/day) users revealed that
ulcers or erosions developed in 48% of patients.3 A multina-
tional prospective study of 187 patients given low-dose
aspirin (75e325 mg daily) for prophylaxis of cardiovascular
diseases revealed that 20% had dyspeptic symptoms. The
same population also had an 11% prevalence of gastric and
duodenal ulcer.4
In patientswith aspirin allergy, aspirin intolerance or history
of peptic ulcer, clopidogrel is a widely used alternative. This
adenosine diphosphate (ADP) receptor antagonist inhibits
platelet aggregation by irreversibly inhibiting ADP-induced
activation of platelet fibrinogen (glycoprotein IIb/IIIa).5 A
recent study showed that clopidogrel induced less gastroduo-
denal injury than aspirin in healthy participants.6 The Clopi-
dogrel versus aspirin in patients at risk of ischemic events
(CAPRIE) trial involving 19,185 patients with mean follow-up of
1.91 years also demonstrated that clopidogrel (75 mg once
daily) was associated with significantly less gastrointestinal
hemorrhage (0.52% vs. 0.72%) and upper gastrointestinal
disturbance (indigestion/nausea/ vomiting) (0.97% vs. 1.22%)
than aspirin (325 mg once daily).7 Nonetheless, a recent
retrospective study reported a 12% frequency of clopidogrel-
associated gastrointestinal bleeding in a high-risk population
withprevious peptic ulcer disease.8 Currently, few studies have
investigated the typical findings of gastrointestinal lesions
associatedwith clopidogrel therapy, though the characteristics
of the gastroduodenal lesions in aspirin therapy are well
studied.
The aims of this prospective study were to investigate
the characteristics of endoscopic findings in clopidogrel
users undergoing endoscopy for upper gastrointestinal
symptoms and to compare the clinical characteristics and
upper gastrointestinal lesions between symptomatic clopi-
dogrel and aspirin users.
Materials and methods
Patients
From January 2009 to December 2010, consecutive outpa-
tients who had received either clopidogrel or aspirinsymptomswere recruited.All of themhadamedical history of
regular clopidogrel or aspirin consumption within 1 month
before endoscopy. The exclusion criteria included: (1) use of
a proton pump inhibitor (PPI) or H2 blocker within the past 1
month before endoscopy; (2) use of warfarin or ticlopidine
within the past 1 month; (3) use of a non-steroidal anti-
inflammatorydrug (NSAID)within thepast 1month; (4) lack of
symptoms; (5) previous gastric operation; and (6) concomi-
tant use of aspirin and clopidogrel.
Study design
Endoscopies were performed with the Olympus GIF XV10
and GIF XQ200 gastroscopes (Olympus Corp., Tokyo, Japan)
after patients had fasted overnight. Upper gastrointestinal
lesions were carefully examined and assessed according to
the Lanza Endoscopic Scoring System.9 The Lanza score is
a categorical score (0e4) of endoscopic upper gastrointes-
tinal erosion and ulcer and mucosal hemorrhage, defined as
follows: score 0Z normal stomach and proximal
duodenum; 1Zmucosal hemorrhage only; 2Z one or two
erosions; 3Z three to ten erosions; 4Z greater than ten
erosions or an ulcer. Erosions were defined as flat white-
based mucosal breaks of any size, and ulcers were
defined as mucosal breaks of 3 mm or more demonstrating
unequivocal depth. Additionally, antrum biopsy was per-
formed for the rapid urease test.10 The following data were
recorded for each participant: age, sex, medical history,
corticosteroid use, history of smoking, alcohol, coffee and
tea consumption, symptom score by questionnaires, history
of H. pylori eradication, co-morbidity, and indication for
the use of anti-platelet agents. Co-morbidity included
hypertension, diabetes mellitus, cerebral vascular acci-
dent, coronary artery disease, congestive heart failure,
cirrhosis and end-stage renal disease. Smoking was defined
as consumption of one pack or more of cigarettes per week.
Coffee or tea consumption was defined as drinking one cup
or more per day. Symptoms of patients were assessed by
a symptom score by Tucci et al.11 Diagnosis of H. pylori
infection was according to a positive result of rapid urease
test.12
Gastrointestinal symptom assessments
A previously validated symptom questionnaire by Tucci
et al.,11 with the symptom score ranging from zero to 12,
was administered to each patient. The questionnaire
assessed four well-categorized dyspeptic symptoms:
epigastric pain or burning, postprandial fullness, nausea
and vomiting. Each symptom was graded as 0e3 according
to its influence on the patients’ activities; 0Z absent;
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levant (diverting from, but not urging modifications of usual
activities); and 3Z severe (interfering with ordinary
activities of the patients).
Rapid urease test
The rapid urease test was performed according to our
previous study.12 Each biopsy specimen was placed imme-
diately in 1 mL of a 10% solution of urea in deionized water
(pH 6.8) to which two drops of 1% phenol red solution was
added, and incubated at 37C for up to 24 hours. If the
yellowish color around the area of inserted specimen
changed to bright pink within the 24-hour limit, the urease
test was considered positive. In our laboratory, the sensi-
tivity and specificity of the rapid urease test are 96% and
91%, respectively.12
Statistical methods
All statistical analyses were performed with the SPSS
program (version 12.0.1C; SPSS Inc. Chicago, UK, USA). The
demographic and clinical characteristics of patients were
compared by Student’s t-test (for age and symptom score)
or c2 test with or without Yates correction (for gender,
smoking, alcohol, coffee, tea, history of gastrointestinal
bleeding, history of peptic ulcer and H. pylori status). The
c2 test or Fisher’s exact test was used to evaluate the risk
of peptic ulcer formation (univariate analysis). Those vari-
ables were subsequently assessed by a logistic regression
method to identify independent risk factors for the devel-
opment of peptic ulcer. All p values are two-sided. A p
value <0.05 was considered to be significant.
Results
Four hundred and thirteen consecutive patients who had
used either aspirin or clopidogrel within 1 month before
endoscopy were examined. Of these, 198 were excluded forTable 1 Baseline characteristics of the 215 patients.
Aspirin (nZ 1
Age (years) (meanSD) 69.4 12.5
Sex (men) 69.7% (76/10
Smoking 11.9% (13/10
Alcohol use 10.1% (11/10
Consumption of coffee 12.8% (14/10
Consumption of tea 21.1% (23/10
Past gastrointestinal bleeding 17.4% (19/10
Past ulcer history 43.1% (47/10
Active H. pylori infection 35.4% (34/96
History of H. pylori eradication 13.8% (15/10
Symptom score (meanSD) 2.2 1.8
Co-morbidity 84.4% (92/10
Indication for the anti-platelet agents
CAD 67.9% (74/10
CVA 25.7% (28/10
CADZ coronary artery disease; CVAZ cerebral vascular accident; SDthe following causes: (1) PPI or H2 blocker use within the
past 1 month (102 patients); (2) warfarin or ticlopidine use
within the past 1 month (21 patients); (3) systemic NSAID
use within the past 1 month (34 patients); (4) lack of
symptoms (28 patients); (5) previous gastric operation
(eight patients); and (6) concomitant use of aspirin and
clopidogrel (five patients). Of the 215 eligible patients, 106
and 109 patients underwent clopidogrel and aspirin
therapy, respectively. Regarding to the baseline charac-
teristics, there were no significant differences in gender,
tobacco use, alcohol use, coffee intake, tea consumption,
co-morbidity, symptom score, and indication for the anti-
platelet drugs between the aspirin and clopidogrel groups
(Table 1). Most patients who received anti-platelet agents
did so for secondary prevention for the coronary artery
events (68% vs. 75%, respectively, pZ 0.756). Compared
with the aspirin group, the clopidogrel group was older
(mean 73 years old vs. 69 years old, respectively,
pZ 0.028) and had higher frequencies of past history of
peptic ulcer (88% vs. 43%, respectively, p< 0.001), past
history of gastrointestinal bleeding (32% vs. 17%, respec-
tively, pZ 0.017), and past history of H. pylori eradication
(26% vs. 14%, respectively, pZ 0.026). By contrast, the
clopidogrel users had a lower frequency of active H. pylori
infection than aspirin users (17% vs. 35%, respectively,
pZ 0.007).
Table 2 shows the endoscopic findings in symptomatic
patients receiving clopidogrel or aspirin therapy. Clopi-
dogrel users had higher frequencies of hemorrhagic spots
(25% vs. 10%, pZ 0.004) and peptic ulcers (39% vs. 24%,
pZ 0.027) than aspirin users. Additionally, the mean Lanza
score in clopidogrel users was higher than that in aspirin
users (2.4 vs. 1.9, pZ 0.043).
Table 3 displays the characteristics of peptic ulcers in
the patients receiving clopidogrel. In the clopidogrel users,
the distributions of peptic ulcers were 78% (32/41), 5% (2/
41) and 17% (7/41) in the stomach, duodenum and both,
respectively. The mean diameter of ulcer in the clopidogrel
group was larger than that in aspirin group (11 7.1 mm
and 7 3.1 mm respectively, pZ 0.001). Most ulcers in09) Clopidogrel (nZ 106) p
73.2 12.1 0.028*
9) 70.8% (75/106) 0.883
9) 12.3% (13/106) 1.000
9) 3.8% (4/106) 0.069
9) 8.8% (12/106) 0.835
9) 18.9% (20/106) 0.735
9) 32.1% (34/106) 0.017*
9) 87.7% (93/106) <0.001*
) 17.0% (15/88) 0.007*
9) 26.4% (28/106) 0.026*
2.2 1.4 0.846
9) 92.5% (98/106) 0.088
0.756
9) 74.5% (79/106)
9) 25.5% (27/106)
Z standard deviation. * p< 0.05.
Table 2 Endoscopic findings in patients with gastrointes-
tinal symptoms receiving clopidogrel or aspirin therapy.
Aspirin
(nZ 109)
Clopidogrel
(nZ 106)
p
Erosive esophagitis 25.7% (28/109) 32.1% (34/106) 0.366
Gastroduodenal
damage
Hemorrhagic spots 10.1% (11/109) 25.5% (27/106) 0.004*
Erosion 53.2% (58/109) 38.7% (41/106) 0.040*
Peptic ulcer 23.9% (26/109) 38.7% (41/106) 0.027*
Lanza score
(mean SD)
1.9 1.6 2.4 1.7 0.043*
SDZ standard deviation. * p< 0.05.
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the stomach. Fig. 1 demonstrates the typical endoscopic
findings of the aspirin and clopidogrel groups.
Univariate analyses demonstrated that history of
smoking (pZ 0.003), past gastrointestinal bleeding history
(pZ 0.001) and clopidogrel (pZ 0.027) were associated
with the presence of peptic ulcer in patients who under-
went clopidogrel or aspirin therapy. Advanced age, gender,
alcohol use, past ulcer history, and current H. pylori
infection were not associated with peptic ulcer risk (Table
4). Multivariate analysis revealed that history of smoking
and past gastrointestinal bleeding history were two inde-
pendent factors related to peptic ulcer risk in symptomatic
patients who had undergone anti-platelet therapy, with
odds ratios of 3.2 (95% CI 1.3e7.8) and 2.6 (95% CI 1.3e5.1),
respectively (Table 5).
Discussion
The current study showed that a significant number of
symptomatic clopidogrel users had hemorrhagic spots
(25%), erosions (39%) and peptic ulcers (39%). Most pepticTable 3 Characteristics of peptic ulcers in patients
receiving clopidogrel or aspirin therapy.
Parameters
of ulcer
Aspirin
(nZ 26)
Clopidogrel
(nZ 41)
p
Size (mm)
(meanSD)
7 3.1 11 7.1 0.001*
Size 0.044*
< 1 cm 69.2% (18/26) 41.5% (17/41)
 1 cm 30.8% (8/26) 58.5% (24/41)
Number 0.767
Single 19.2% (5/26) 24.4% (10/41)
Multiple 80.8 (21/26) 75.6% (31/41)
Location 0.341
Stomach 69.2% (18/26) 78.0% (32/41)
Duodenum 15.4% (4/26) 4.9% (2/41)
Stomach and
duodenum
15.4% (4/26) 17% (7/41)
SDZ standard deviation. * p< 0.05.ulcers in clopidogrel users were located in the stomach.
Compared with symptomatic aspirin users, symptomatic
clopidogrel users had higher frequencies of hemorrhagic
spots and peptic ulcer. Additionally, the mean diameter of
ulcer in symptomatic clopidogrel users was larger than that
in aspirin users. These data indicate that gastroduodenal
erosions or ulcers are common endoscopic findings in
symptomatic clopidogrel users and endoscopic surveillance
is warranted for symptomatic patients who undergo clopi-
dogrel therapy.
Currently, the mechanisms of ulcer formation in patients
receiving clopidogrel therapy are unclear. However, it has
been hypothesized that ADP receptor antagonists may
cause gastrointestinal injury through an impairment of
ulcer healing.13,14 Platelet aggregation may play an
important role in ulcer healing through the release of
various platelet-derived growth factors that promote
angiogenesis and ulcer healing. An animal study revealed
that thrombocytopenic rats have impaired healing of
gastric ulcers.15 ADP receptor antagonists may impair
gastric ulcer healing by suppressing the release of platelet-
derived growth factors.15
In this study, the symptomatic clopidogrel users had
higher frequencies of past history of peptic ulcer (88% vs.
43%, respectively, p< 0.001) and past history of gastroin-
testinal bleeding (32% vs. 17%, respectively, pZ 0.017)
than symptomatic aspirin users. Because clopidogrel is
much more expensive than aspirin, it is often reserved for
the atherosclerotic patients with aspirin intolerance in
clinical practice. According to the Guidelines of Taiwan
Bureau of National Health Insurance, clopidogrel can be
only prescribed for the patients with a history of peptic
ulcer, aspirin allergy and aspirin intolerance. This strict
regulation was possibly the most important factor that led
to the demographic differences between symptomatic
clopidogrel and aspirin users in this study.
Our study also showed that the clopidogrel users had
a lower frequency of active H. pylori infection than aspirin
users (17% vs. 35%, respectively). However, the frequency
of past history of H. pylori eradication in the clopidogrel
group was higher than that in the aspirin group (26.4% vs.
13.8%, respectively; pZ 0.026). We therefore proposed
that the low frequency of active H. pylori infection in
clopidogrel users was possibly due to previous anti-H. pylori
therapy.
Although clopidogrel is less likely to induce gastroin-
testinal bleeding than aspirin,16 the current study showed
the clopidogrel users had higher prevalence of hemorrhagic
spots and peptic ulcers. Additionally, the mean Lanza score
in clopidogrel users was higher than that in aspirin users
(2.4 vs. 1.9). The more severe gastroduodenal damage in
symptomatic clopidogrel users might be due to the differ-
ences in the clinical background and ulcer diathesis
between clopidogrel and aspirin users.
In this study, multivariate analyses revealed that history
of smoking and past gastrointestinal bleeding history were
two independent predictors of peptic ulcer in symptomatic
patients who had undergone anti-platelet therapy with odd
ratios of 3.2 and 2.6, respectively. Other clinical factors,
such as advanced age, gender, alcohol consumption, history
of peptic ulcer, and H. pylori status, did not affect the risk
of peptic ulcer in symptomatic anti-platelet agent users.
Figure 1 Typical endoscopic findings. (A) Multiple tiny ulcers and erosions at the whole antrum in a 79-year-old male patient
receiving aspirin for prevention of coronary artery disease. (B) Multiple polygonal large ulcers at the whole antrum in a 80-year-old
female patient receiving clopidogrel for prevention of coronary artery disease.
Table 4 Univariate analysis of the risk factors for peptic
ulcers in symptomatic patients receiving anti-platelet
therapy.
Principal variables Number
of cases
Number
of peptic
ulcers
p
Age 1.000
60 years 187 58
<60 years 28 9
Sex 0.630
Male 151 49
Female 64 18
Smoking 0.003*
(þ) 26 15
(e) 189 52
Alcohol 0.697
(þ) 15 4
(e) 200 63
Past ulcer history 0.758
(þ) 140 45
(e) 75 22
Past GI bleeding history 0.001*
(þ) 53 27
(e) 162 40
Active H. pylori infection 0.394
(þ) 51 20
(e) 135 44
History of H. pylori eradication 0.27
(þ) 43 10
(e) 173 57 0.027*
Type of anti-platelet agent
Aspirin 109 26
Clopidogrel 106 41
GIZ gastrointestinal. * p< 0.05.
Upper gastrointestinal lesions and clopidogrel 709Previous studies also demonstrated that smoking is a risk
factor for peptic ulcer disease and affects the healing of
peptic ulcers.16 Cigarette smokers are known to have
decreased prostaglandin concentrations in gastric and
duodenal mucosa, which is a possible mechanism of peptic
ulcer formation and healing.17 History of gastrointestinal
bleeding was the other independent factor associated with
ulcer development in this study. This finding is consistent
with another independent study showing that history of
gastrointestinal bleeding is associated with increased inci-
dence of gastrointestinal bleeding in clopidogrel users.18
In conclusion, hemorrhagic spots, gastroduodenal
erosions and ulcers are common endoscopic findings in
symptomatic clopidogrel users. Most peptic ulcers in clo-
pidogrel users are located in the stomach. The frequencies
of hemorrhagic spots and peptic ulcers in symptomatic
clopidogrel users are higher than those in symptomatic
aspirin users.
The patients who received clopidogrel had more
hemorrhagic spots, peptic ulcers and higher Lanza score.
Smoking and past gastrointestinal bleeding history were
two independent factors associated with the risk of peptic
ulcer in patients receiving anti-platelet therapy. Aggressive
survey for gastrointestinal lesions is warranted for symp-
tomatic clopidogrel users, especially in those with history
of smoking and past gastrointestinal bleeding history.Table 5 Multivariate analysis of the risk factors for peptic
ulcer in symptomatic patients receiving anti-platelet
therapy.
Risk factor Coefficient SE p OR 95% CI
Smoking 1.173 0.450 0.009* 3.232 1.339e7.801
Past GI
bleeding
history
0.958 0.343 0.005* 2.606 1.330e5.109
Clopidogrel 0.602 0.317 0.058 1.825 0.981e3.397
CIZ confidence interval; GIZ gastrointestinal; ORZ odds
ratio; SEZ standard error. * p< 0.05.
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